A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT07541170 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Divarasib
DRUG: Pembrolizumab
DRUG: Nivolumab

Sponsor

Hoffmann-La Roche